Document:

EX-10.10

 Exhibit 10.10 

ORCHARD THERAPEUTICS PLC 

2018 EMPLOYEE SHARE PURCHASE PLAN 

The purpose of the Orchard Therapeutics plc 2018 Employee Share Purchase Plan (the “Plan”) is to provide eligible employees
of Orchard Therapeutics plc (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase Shares. 850,948 Shares in the aggregate have been approved and reserved for this purpose, plus
on January 1, 2019 and each January 1 thereafter through January 1, 2028, the number of Shares reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1,500,000 Ordinary Shares,
(ii) one percent (1 %) of the number of Shares issued and outstanding on the immediately preceding December 31st, or (iii) such lesser number of Shares as determined by the
Administrator.    The Plan is intended to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “U.S. Code”),
and shall be interpreted in accordance with that intent. 
 1.    Administration. The Plan will be administered
by the person or persons (the “Administrator”) appointed by the Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such
rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for
the administration of the Plan; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all
persons, including the Company and the Participants. No member of the Board or individual exercising 
  

 administrative authority with respect to the Plan shall be liable for any action or determination made in
good faith with respect to the Plan or any option granted hereunder. 
 2.    Offerings. The Company will make
one or more offerings to eligible employees to purchase Shares under the Plan (“Offerings”). Unless otherwise determined by the Administrator, the initial Offering will begin on the Registration Date and will end on the following
May 31, 2019 (the “Initial Offering”). Thereafter, unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each June 1 and December 1 and will end on
the last business day occurring on or before the following November 30 and May 31, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in
duration or overlap any other Offering. 
 3.    Eligibility. All individuals classified as employees on the
payroll records of the Company and each Designated Subsidiary are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the “Offering Date”) they
are customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and have completed at least 30 days of employment. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as
employees of the Company or a Designated Subsidiary for purposes of the Company’s or applicable Designated Subsidiary’s payroll system are not considered to be eligible employees of the Company or any Designated Subsidiary and shall not be
eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Subsidiary for any purpose, including, without limitation, common 

  
 2 

 
law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding,
such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a
Designated Subsidiary on the Company’s or Designated Subsidiary’s payroll system to become eligible to participate in this Plan is through an amendment to this Plan, duly executed by the Company, which specifically renders such individuals
eligible to participate herein. 
 4.    Participation. 

(a)    Participants on Effective Date. Each eligible employee as of the Registration Date shall be deemed to be a
Participant at such time. If an eligible employee is deemed to be a Participant pursuant to this Section 4(a), such individual shall be deemed not to have authorized payroll deductions and shall not purchase any Shares hereunder unless he or
she thereafter authorizes payroll deductions by submitting an enrollment form (in the manner described in Section 4(c)) within 60 days of the commencement of the Initial Offering. If such a Participant does not authorize payroll deductions by
submitting an enrollment form within 60 days of the commencement of the Initial Offering, that Participant will be deemed to have withdrawn from the Plan. 

(b)    An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by
submitting an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). 

  
 3 

 (c)    Enrollment. The enrollment form will (a) state a
whole percentage or the amount to be deducted from an eligible employee’s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Shares in each Offering in accordance with the terms of the Plan and
(c) specify the exact name or names in which Shares purchased for such individual are to be issued pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to
participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such Participant’s deductions and purchases will continue at the same percentage or amount of Compensation for future Offerings, provided he or she
remains eligible. 
 (d)    Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be
denied contrary to the requirements of the U.S. Code. 
 5.    Employee Contributions. Each eligible employee may
authorize payroll deductions at a minimum of 1 percent up to a maximum of 15 percent of such employee’s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each
Participant for each Offering. No interest will accrue or be paid on payroll deductions. 
 6.    Deduction
Changes. Except in the event of a Participant increasing his or her payroll deduction from 0 percent during the first Offering as specified in Section 4(a) as may be determined by the Administrator in advance of an Offering, a
Participant may not increase or decrease his or her payroll deduction during any Offering, but may increase or decrease his or her payroll deduction with respect to the next Offering (subject to the limitations of Section 5) by filing a new
enrollment form at least 15 business days before the next Offering Date (or by such 

  
 4 

 
other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or
terminate his or her payroll deduction during an Offering. 
 7.    Withdrawal. A Participant may withdraw from
participation in the Plan by delivering a written notice of withdrawal to his or her appropriate payroll location. The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s withdrawal, the
Company will promptly refund such individual’s entire account balance under the Plan to him or her (after payment for any Shares purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not
begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4. 

8.    Grant of Options. On each Offering Date, the Company will grant to each eligible employee who is then a
Participant in the Plan an option (“Option”) to purchase on the last day of such Offering (the “Exercise Date”), at the Option Price hereinafter provided for, the lowest of (a) a number of Shares determined by
dividing such Participant’s accumulated payroll deductions on such Exercise Date by the lower of (i) 85 percent of the Fair Market Value of the Shares on the Offering Date, or (ii) 85 percent of the Fair Market Value of the
Shares on the Exercise Date, (b) a number of Shares determined dividing $50,000 by the Fair Market Value of the Shares on the Offering Date; or (c) such other lesser maximum number of Shares as shall have been established by the
Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such Participant’s accumulated payroll
deductions on the Exercise Date. 

  
 5 

 
The purchase price for each share purchased under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Shares on the Offering Date or the
Exercise Date, whichever is less. 
 Notwithstanding the foregoing, no Participant may be granted an option hereunder if such Participant,
immediately after the option was granted, would be treated as owning shares possessing 5 percent or more of the total combined voting power or value of all classes of shares of the Company or any Parent or Subsidiary (as defined in
Section 11). For purposes of the preceding sentence, the attribution rules of Section 424(d) of the U.S. Code shall apply in determining the share ownership of a Participant, and all shares which the Participant has a contractual right to
purchase shall be treated as shares owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase Shares under the Plan, and any other employee share purchase plan of the Company and its
Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such Shares (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the
limitation in the preceding sentence is to comply with Section 423(b)(8) of the U.S. Code and shall be applied taking Options into account in the order in which they were granted. 

9.    Exercise of Option and Purchase of Shares. Each employee who continues to be a Participant in the Plan on the
Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole Shares reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will
purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant’s account at the end of an Offering solely by reason of the inability to purchase a

  
 6 

 
fractional share will be carried forward to the next Offering; any other balance remaining in a Participant’s account at the end of an Offering will be refunded to the Participant promptly.

 10.    Issuance of Certificates. Certificates representing Shares purchased under the Plan may be issued only
in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose. 

11.    Definitions. 

The term “ADSs” means American Depositary Shares, representing Ordinary Shares on deposit with a U.S. banking institution selected
by the Company. 
 The term “Compensation” means the amount of base pay, prior to salary reduction pursuant to Sections 125,
132(f) or 401(k) of the U.S. Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company share options,
and similar items. 
 The term “Designated Subsidiary” means any present or future Subsidiary (as defined below) that has been
designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the shareholders. The current list of
Designated Subsidiaries is attached hereto as Appendix A. 
 The term “Fair Market Value of the Shares” on any given date means
the fair market value of the Shares determined in good faith by the Administrator; provided, however, that if the ADSs are admitted to quotation on the National Association of Securities Dealers Automated Quotation System
(“NASDAQ”), NASDAQ Global Market or another national securities 

  
 7 

 
exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date
preceding such date for which there is a closing price. Notwithstanding the foregoing, if the date for which the Fair Market Value of the Shares is determined is the Registration Date, the Fair Market Value of the Shares shall be determined based
upon the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s initial public offering. 

The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the U.S.
Code. 
 The term “Ordinary Shares” mean ordinary shares in the Company, with a nominal value of £0.10 per share. 

The term “Participant” means an individual who is eligible as determined in Section 3 and who has complied with the provisions
of Section 4. 
 The term “Registration Date” means the date upon which the registration statement on Form F-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission 

The term “Share” means an Ordinary Share and/or the number of ADSs equal to an Ordinary Share, as the context may require 

The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of
the U.S. Code. 
 12.    Rights on Termination of Employment. If a Participant’s employment terminates for
any reason before the Exercise Date for any Offering, no payroll deduction will be taken 

  
 8 

 
from any pay due and owing to the Participant and the balance in the Participant’s account will be paid to such Participant or, in the case of such Participant’s death, to his or her
designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. In the case of Participants who are employed in the UK, the termination date of their employment will be the date they give, or are given, notice of
termination of their employment unless the Administrator decides that it shall be a later date before the statutory or contractual expiry date of their notice period. An employee will be deemed to have terminated employment, for this purpose, if the
corporation that employs him or her, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An employee will not be deemed to have
terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee’s right to reemployment is guaranteed either by a
statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing. 

If a Participant ceases to be employed by the Company or any Subsidiary for any reason whatsoever (including as a result of being wrongfully
or unfairly dismissed) they shall not be entitled, and by participating in this Plan they shall be deemed to have waived any possible entitlement, to any sum or benefit accrued or in prospect as a result of that participation and no such loss or
curtailment shall form part of any claim for damages for breach of the Participant’s contract of employment or compensation for dismissal or any other claim whatsoever. 

13.    Special Rules. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules
applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate 

  
 9 

 
for the implementation of the Plan in a jurisdiction where such Designated Subsidiary has employees; provided that such rules are consistent with the requirements of Section 423(b) of the
U.S. Code. Any special rules established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan. 

14.    Optionees Not Shareholders. Neither the granting of an Option to a Participant nor the deductions from his
or her pay shall constitute such Participant a holder of the Shares covered by an Option under the Plan until such Shares have been purchased by and issued to him or her. 

15.    Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or
the laws of descent and distribution, and are exercisable during the Participant’s lifetime only by the Participant. 

16.    Application of Funds. All funds received or held by the Company under the Plan may be combined with other
corporate funds and may be used for any corporate purpose. 
 17.    Adjustment in Case of Changes Affecting
Shares. In the event of a subdivision of outstanding Shares, the payment of a dividend in Shares or any other change affecting the Shares, the number of Shares approved for the Plan and the share limitation set forth in Section 8 shall be
equitably or proportionately adjusted to give proper effect to such event. 
 18.    Amendment of the Plan. The
Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the shareholders, no amendment shall be made increasing the number of Shares approved for the Plan
or making any other change that would require shareholder approval in 

  
 10 

 
order for the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the U.S. Code. 

19.    Insufficient Shares. If the total number of Shares that would otherwise be purchased on any Exercise Date
plus the number of Shares purchased under previous Offerings under the Plan exceeds the maximum number of Shares issuable under the Plan, the Shares then available shall be apportioned among Participants in proportion to the amount of payroll
deductions accumulated on behalf of each Participant that would otherwise be used to purchase Shares on such Exercise Date. 

20.    Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan,
all amounts in the accounts of Participants shall be promptly refunded. 
 21.    Governmental Regulations. The
Company’s obligation to sell and deliver Shares under the Plan is subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such Shares. 

22.    Governing Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in
accordance with, the law of England and Wales, applied without regard to conflict of law principles. 

23.    Issuance of Shares. Shares may be issued upon exercise of an Option from authorized but unissued Shares,
from Shares held in the treasury of the Company, or from any other proper source. 
 24.    Tax Withholding.
Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to
deduct 
  

  
 11 

 
any such taxes from any payment of any kind otherwise due to the Participant, including Shares issuable under the Plan. For this purposes “tax” shall mean Federal, state and local taxes
and social security taxes in the US, and their equivalent in any other jurisdiction, for which a Participant is liable by reason of the acquisition, holding or disposal of Shares under the Plan or the receipt of any other benefit in connection with
it and which the Company or any Subsidiary is liable to account for on the Participant’s behalf. 

25.    Notification Upon Sale of Shares. Each Participant agrees, by entering the Plan, to give the Company prompt
notice of any disposition of Shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such Shares were purchased or within one year after the date such Shares were
purchased. 
 26.    Effective Date and Approval of Shareholders. The Plan shall take effect upon the date
immediately preceding the Registration Date following shareholder approval in accordance with applicable law. 

  
 12 

 APPENDIX A 

Designated Subsidiaries 
 Orchard
Therapeutics (Europe) Limited 
 Orchard Therapeutics North America 

Orchard Therapeutics (Netherlands) B.V. 

  
 13EX-10.11

 Exhibit 10.11 

DIRECTOR NOMINATION AGREEMENT 

THIS DIRECTOR NOMINATION AGREEMENT is dated as of October 18, 2018 (this “Agreement”), by and between Orchard Rx Limited
(which will re-named and re-registered as a public limited company prior to the IPO (as defined below) at which point the company will be named Orchard Therapeutics plc,
a public limited company incorporated under the laws of England and Wales (the “Company”), and Glaxo Group Limited, a company incorporated under the laws of England (“GSK”), and is effective as of, and conditioned
upon, the closing of the Company’s initial public offering (“IPO”) of American Depository Shares (“ADSs”), each ADS representing one ordinary share of the Company, on the Nasdaq Stock Market (the
“Effective Date”). 
 WHEREAS, GSK, GlaxoSmithKline Intellectual Property Development Ltd. and Oxford Therapeutics (Europe)
Limited (previously known as Orchard Therapeutics Limited and now a wholly-owned subsidiary of the Company as a result of a corporate reorganization effected in connection with the IPO) are party to that certain Asset Purchase and License Agreement,
dated 11 April 2018 (the “APA”), pursuant to which GSK transferred to the Company its portfolio of approved and investigational rare disease gene therapies. 

WHEREAS, in light of the foregoing, the parties now desire to set forth the terms of GSK’s right to designate a director nominee of the
Company following the Company’s IPO. 
 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants and
agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows: 

1.    Nomination of Director. 

(a)    Effective as of the Effective Date and until the date on which one (1) MLD Royalty Product (as defined in the
APA), in respect of which Orchard Therapeutics (Europe) Limited has obtained a marketing authorization or biologics license application and made the first bona fide commercial sale for which revenue has been recognized (the “Director
Nomination Term”), as further described below, GSK shall have the right to nominate one (1) individual reasonably acceptable to the Company (the “Nominee”) to serve on the Board of Directors of the Company (the
“Board”) as a Class III director. 
 Subject to Section 1(b), during the Director Nomination Term, the Board and
all applicable committees and subcommittees thereof shall take all action necessary so that the Nominee shall stand for election by the Company’s shareholders (the “Shareholders”) at each annual general meeting of the Company
at which Class III directors are required to stand for re-election (each, an “Annual Meeting”), it being understood that the next such Annual Meeting is scheduled for the year 2021. The
Company agrees to (i) include the Nominee in any proxy statement or written consent prepared by the Company for each such Annual Meeting and recommend and solicit proxies for the election of the Nominee at each such Annual Meeting (and at every
adjournment or postponement thereof), (ii) cause all ordinary shares represented by proxies granted to it (or any of its officers, directors or representatives) to be voted in favor of 

 
the Nominee, and (iii) otherwise support the Nominee for election in a manner no less rigorous and favorable than the manner in which the Company supports its other nominees. 

(b)    As a condition to the nomination of the Nominee in accordance with this Section 1, the Nominee shall provide
any information that the Company reasonably requires, including without limitation information required to be disclosed in a proxy statement or other filing under applicable law, stock exchange rules or listing standards and information in
connection with assessing eligibility, independence or other criteria applicable to directors under applicable law, stock exchange rules or listing standards. If, at any time (including without limitation, prior to the Nominee’s election or re-election to the Board), the Board learns of a Disqualifying Event (as defined below), then the Board may, in its sole discretion, (i) not take any of the actions required by Section 1(a) above (and the
Company shall have no obligations pursuant to Section 1(a) above), or (ii) if the Nominee is then serving on the Board, request that the Nominee resign from the Board and any committees thereof (a “Resignation Request”).
Immediately following delivery of a Resignation Request to the Nominee, the Nominee shall take any and all actions to resign from the Board and any committees thereof which shall be effective immediately and in the absence of such resignation, the
Board may remove the Nominee from the Board without the consent of the Nominee. A “Disqualifying Event” means any of the following: (x) conduct by the Nominee that is or would reasonably be expected to be materially harmful to
the business, interests or reputation of the Company, it being understood that the Nominee’s commission of, being indicted or charged with, or making a plea of nolo contendere to a felony or a misdemeanor involving moral turpitude,
deceit, dishonesty or fraud shall be deemed materially harmful to the business of the Company; or (y) the Nominee’s material violation of any provision of any Company Policy (as defined below) or any agreement(s) between the Nominee and
the Company (and/or any of its Affiliates (as defined below)). As used herein, “Affiliate” means, with respect to any specified person or entity, any other person or entity that directly, or indirectly, controls or is controlled by,
or is under common control with, such person or entity. 
 (c)    GSK and the Company acknowledge that the Nominee,
subject to and upon election to the Board, shall serve as a member of the Board and shall be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related-party transactions, fiduciary duties, codes of
conduct, trading and disclosure policies, director resignation policies, and corporate governance policies of the Company (each, a “Company Policy” and collectively, the “Company Policies”) as other directors
(including, for the avoidance of doubt, such obligations as may be imposed by applicable law), and shall be required to preserve the confidentiality of, and not disclose, any non-public information of the
Company or any of its subsidiaries, including discussions or matters considered in meetings of the Board or any committees or subcommittees thereof, and shall have the same rights and benefits, including with respect to insurance, indemnification,
compensation and fees, as are applicable to all non-employee directors of the Company. Notwithstanding the foregoing, no confidentiality policy or obligation shall preclude the Nominee from sharing information
with GSK and its Affiliates, provided that GSK and its Affiliates shall maintain any such information as strictly confidential and shall not disclose any such information to any third party, and provided further that any such information shall be
used by GSK and its Affiliates solely for purposes of evaluating, monitoring and managing GSK’s investment in the Company and for no other purpose. 

  
 2 

 (d)    As a condition to the Nominee’s election or re-election to the Board, as applicable, the Nominee shall agree to sign all documents required to be signed by members of the Board, consistent with past practices, including without limitation the Company’s
Code of Business Conduct and Ethics and Insider Trading Policy. 
 (e)    Notwithstanding anything to the contrary
herein, the Nominee may be excluded from access to any material or meeting or portion thereof if a majority of the directors (excluding the Nominee) of the Board reasonably determine in good faith that such exclusion is reasonably necessary in the
event of a conflict of interest. 
 2.    Replacement of Director Designated by GSK. From and after the Effective
Date and during the Director Nomination Term, in the event that any Nominee shall fail to be elected at an Annual Meeting, or shall cease to serve as a director for any reason, (i) the vacancy resulting therefrom shall be not be filled until
GSK has designated a replacement and, (ii) the directors then in office will elect such designated replacement to fill the resulting vacancy as soon as practicable following GSK’s designation of a replacement. 

3.    Change in Classification of the Board. Except as required by applicable law, stock exchange rules or listing
standards, from and after the Effective Date and during the Director Nomination Term, in the event the Company takes any action to alter, remove or amend the classification of the Board into three groups of directors with staggered three-year terms,
then the obligations set forth in Section 1 of this Agreement shall apply at any annual meeting or special meeting of the Company at which the director nominated by GSK (including without limitation directors in the same class as such director)
shall be entitled to stand for re-election (and Section 1 of this Agreement shall be construed accordingly). 

4.    Specific Performance. Each of GSK, on the one hand, and the Company, on the other hand, acknowledges and
agrees that irreparable injury to the other would occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately
compensable by the remedies available at law (including the payment of money damages). It is accordingly agreed that GSK, on the one hand, and the Company, on the other hand (in either case, the “Moving Party”), shall each be
entitled to specific enforcement of, and injunctive relief to prevent any violation of, the terms hereof, and the other will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other
remedy or relief is available at law or in equity. This Section 4 is not the exclusive remedy for any violation of this Agreement. 

5.    Severability. If any provision of this Agreement or the application thereof, becomes or is declared by a
court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably
to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and
other purposes of such void or unenforceable provision. 

  
 3 

 6.    Term and Termination; Withdrawal from Agreement; Survival.
This Agreement will commence as of the Effective Date and shall remain in effect until the end of the Director Nomination Term, unless sooner terminated by mutual agreement or pursuant to the following sentence. GSK may at any time elect, by giving
written notice of withdrawal to the Company, to terminate this Agreement. The confidentiality and non-use obligations set forth in Section 1(c) and Sections 4 through 11 shall survive the expiration or
termination of this Agreement. All other rights and obligations will terminate upon the expiration or termination of this Agreement. 

7.    Notices. All notices and other communications hereunder shall be in writing and shall be deemed delivered,
given and received (a) when delivered in person, (b) when transmitted by facsimile (with written confirmation of completed transmission), (c) on the third (3rd) business day following the mailing thereof by certified or registered mail
(return receipt requested) or (d) when delivered by an express courier (with written confirmation of delivery) to the parties hereto at the following addresses (or to such other address or facsimile number as such party may have specified in a
written notice given to the other parties): 
 (i)    if to the Company, to: 

Orchard Therapeutics plc 
 108
Cannon Street 
 London EC4N 6EU 

United Kingdom 
 Attention:
General Counsel 
 with a copy (which shall not constitute notice) to: 

Goodwin Procter LLP 
 100 Northern
Avenue 
 Boston, MA 02210 

Attention: Michael Bison 

Facsimile No.: (617) 523-1231 

(ii)    if to GSK, to: 

Glaxo Group Limited 
 980 Great
West Road 
 Brentford, Middlesex 

TW8 9GS, England 
 with a copy
(which shall not constitute notice) to: 
 King & Spalding International LLP 

125 Old Broad Street 
 London 

EC2N 1AR 
 Attn: Marcus Young 

  
 4 

 and 

SVP BDTT, GSK Legal, 
 GSK House

 980 Great West Road, 

Brentford, Middlesex 
 TW8 9GS,
England 
 Dispute Resolution.    The parties irrevocably agree that the courts of England have exclusive jurisdiction to settle
any dispute or claim that arises out of or in connection with this Agreement or its subject matter or formation (including non-contractual disputes or claims). 

8.    Governing Law. The construction, validity and performance of this Agreement and all non-contractual obligations arising from or connected with this Agreement shall be governed by English law. 

9.    Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered
one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same counterpart. Until and unless
each party has received a counterpart hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other
communication). Any signature page delivered electronically or by facsimile (including transmission by Portable Document Format or other fixed image form) shall be binding to the same extent as an original signature page. 

10.    Miscellaneous. This Agreement (a) constitutes the entire agreement among the parties with respect to
the subject matter hereof and supersedes all prior agreements and understandings both written and oral, among the parties with respect to the subject matter hereof, and (b) shall not be assigned by operation of law or otherwise, except that GSK
may assign its rights and delegate its obligations hereunder to assign its rights and delegate its obligations hereunder to an Affiliate as long as GSK remains ultimately liable for all of GSK’s obligations hereunder (or such GSK Affiliate
executes a deed of adherence to this Agreement pursuant to which such Affiliate agrees to be bound by the terms hereof). 
 [The remainder of
this page intentionally left blank] 

  
 5 

 IN WITNESS WHEREOF, this Director Nomination Agreement has been duly executed and
delivered by the duly authorized signatories of the parties as of the date hereof. 
  
  

			
	ORCHARD RX LIMITED
		
	By:	 	 
	 Name:

Title:
	 	

  
  
  

			
	 GSK:
  

GLAXO GROUP LIMITED

		
	By:	 	 
	 Name:

Title:
	 	

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]